Answer
All patients receiving Remicade (infliximab) must be observed for at least 1–2 hours after infusion for acute infusion-related reactions.
Sources for this answer
- Remicade 100mg powder for concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 75Document updated
Sources checked